Speaker Name: Dr. Yehuda Handelsman, Medical Director and Principal Investigator, Metabolic Institute of America, United States.

Follow this session to:

• Evaluate how early SGLT2i-based therapy may address therapeutic inertia in T2DM.
• Assess how SGLT2i-based FDCs may improve glycemic control and adherence.
• Compare SGLT2i combinations with SU-based regimens for HbA1c, weight, BP, and renal outcomes.
• Review key trial evidence supporting SGLT2i benefits in CV outcomes, HF, and CKD.
• Interpret guideline updates positioning SGLT2i earlier in T2DM management.